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Abstract
Background: We have recently demonstrated that palmitoleic acid (16:1n7) increases lipolysis, glucose uptake and
glucose utilization for energy production in white adipose cells. In the present study, we tested the hypothesis that
palmitoleic acid modulates bioenergetic activity in white adipocytes.
Methods: For this, 3 T3-L1 pre-adipocytes were differentiated into mature adipocytes in the presence (or absence)
of palmitic (16:0) or palmitoleic (16:1n7) acid at 100 or 200 μM. The following parameters were evaluated: lipolysis,
lipogenesis, fatty acid (FA) oxidation, ATP content, oxygen consumption, mitochondrial mass, citrate synthase
activity and protein content of mitochondrial oxidative phosphorylation (OXPHOS) complexes.
Results: Treatment with 16:1n7 during 9 days raised basal and isoproterenol-stimulated lipolysis, FA incorporation
into triacylglycerol (TAG), FA oxidation, oxygen consumption, protein expression of subunits representing OXPHOS
complex II, III, and V and intracellular ATP content. These effects were not observed in adipocytes treated with 16:0.
Conclusions: Palmitoleic acid, by concerted action on lipolysis, FA esterification, mitochondrial FA oxidation, oxygen
consumption and ATP content, does enhance white adipocyte energy expenditure and may act as local hormone.
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Background
White adipose tissue (WAT) stores triacylglycerol (TAG)
and its metabolic feature involves lipogenesis and lipolysis,
which are associated with changes in the volume of ma-
ture adipocytes. The activities of these two metabolic
pathways vary with the need to incorporate or release fatty
acids (FA), which depends on the nutritional status of the
individuals, energy expenditure, hormone levels (e.g. insu-
lin), activities of the enzymes involved in these processes
(e.g. ATGL and HSL, FAS and G6PDH) and the hetero-
geneity existing among white adipose tissue depots [1–3].
Mitochondria play an important role in cellular func-
tion, not only as a major site of ATP production, but also
by regulating energy expenditure, apoptosis signaling and
production of reactive oxygen species [4]. The impact of
mitochondria function and dysfunction on pre-adipocyte
and adipocyte metabolism has attracted a growing body of
interest over the last decade [5–7]. There are several
reports linking mitochondrial dysfunction with impaired
WAT energetic metabolism and the development of obes-
ity, insulin resistance and type 2 diabetes mellitus (T2DM)
[6, 8, 9]. Mitochondria are the main site for aerobic glu-
cose and fatty acid oxidation, oxygen consumption, and
generation of reactive oxygen species and ATP, which are
associated with enhanced basal metabolic rate [10, 11].
Therefore, mitochondria function in WAT might play a
key role to control basal metabolic rate and should be
considered as a target to be investigated for the develop-
ment of alternative therapies to treat/prevent obesity and
related metabolic disorders.
Among several types of lipids produced and released
by adipocytes, palmitoleic acid, a ω-7 monounsaturated
fatty acid (16:1n7, n7) synthesized by the desaturation of
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palmitic acid (16:0) by stearoyl-CoA desaturase 1 (SCD1)
activity, has been shown to act systemically in peripheral
tissues modulating important metabolic processes. Cao
and cols [12] showed that palmitoleic acid improves insu-
lin resistance in skeletal muscle and liver and prevents
hepatosteatosis. As palmitoleic acid is produced and
secreted by WAT, Cao and cols., 2008 [12] named it “lipo-
kine”. Palmitoleic acid treatment leads to increased glu-
cose uptake, AKT phosphorylation and raises GLUT1
and GLUT4 protein levels in plasma membrane of
skeletal muscle cells [13, 14]. Moreover, palmitoleic
acid treatment also enhances AKT, insulin receptor,
insulin receptor substrate-1 and 2 protein phosphoryl-
ation in the liver [12, 15] and exerts cytoprotective
effects in pancreatic β-cells [16, 17].
We investigated herein the effects of palmitoleic acid
on WAT bioenergetics. Recently, our group has shown
that palmitoleic acid treatment increases adipocyte lip-
olysis and the content of the major lipases (ATGL and
HSL) through a PPARα-dependent mechanism [18]. Be-
sides, this lipokine enhanced glucose uptake and GLUT4
content associated with AMPK activation in these cells,
favoring cellular glucose utilization towards energy pro-
duction [19]. Our hypothesis is that palmitoleic acid
increases white adipocyte basal metabolism. To test this
proposition, 3 T3-L1 adipocytes were treated with pal-
mitoleic acid (100 μM) for 9 days. The results were com-
pared with those obtained with palmitic acid and vehicle
under similar experimental protocol. Lipolysis, FA in-
corporation into lipids and FA conversion into CO2, as
well as parameters of mitochondrial bioenergetics (fatty
acid oxidation, oxygen consumption and ATP content)
and proteic analysis of subunits representing OXPHOS
complex (I, II, III, IV e V) were investigated. Treatment
with palmitoleic acid did enhance mitochondrial activity
as indicated by enhanced ATP generation, proteic ex-
pression of II, III, and V complexes of the mitochondrial
electron transport chain, FA oxidation and oxygen con-
sumption. Taken together, boosted mitochondrial bio-
energetics in combination with raised lipolysis and FA
reesterification leads to increased adipocyte energy ex-
penditure via TAG/FA cycle stimulation (futile cycle).
Therefore, palmitoleic acid plays a relevant role in WAT
metabolism and should be considered as a candidate to
be tested in obesity-related therapies.
Methods
Cell culture
3 T3-L1 preadipocytes were cultured in Dulbeccos Modi-
fied Eagle Medium (DMEM) containing 10% calf serum
and 1% penicillin-streptomycin until confluence. Differen-
tiation was induced 2 days post-confluence by addition of
dexamethasone (1 μM), isobutylmethylxanthine (0.5 mM),
insulin (1.67 μM), and 10% fetal bovine serum (FBS). After
48 h, medium was replaced by DMEM containing 10%
FBS and 0.41 μM insulin [20]. Cells were cultivated for
9 days in the presence of palmitic acid (16:0), palmitoleic
acid (16:1n7), each at 100 μM dissolved in ethanol
0.05% (vehicle), starting from the first day of differenti-
ation (day 0). This dose of palmitoleic acid was found
to have no cytotoxic or deleterious effects on cells as
evaluated by plasma membrane integrity and DNA
fragmentation during differentiation until the day 9
[21]. As we demonstrated before (18) that the palmito-
leic acid effects in adipocytes are structure specific,
here, we did not add more additional control such as
oleic acid (18:1n9) to the cell cultures. In some experi-
ments, etomoxir (Sigma-Aldrich), an inhibitor of CPT-
1 activity, was used to inhibit fatty acid oxidation at a
concentration of 40 μM, added 24 h before the experi-
ments. Cell culture medium was changed every 2 days.
All reagents and drugs were purchased from Sigma
Chemical Company (St. Louis, MO, USA). Similar pro-
cedure was used in our previous studies [18].
Lipolysis measurement
Lipolysis was estimated as the rate of glycerol (Free
Glycerol Determination Kit, Sigma) and free fatty acid
(FFA) (NEFA Kit RH series, Wako Diagnostics, CA,
USA) released from differentiated 3 T3-L1 cells after
9-day treatment with the fatty acids or vehicle (in
some experiments with or without etomoxir) during
30 min of incubation. Similar procedure was used in
our previous studies [18, 22]. Results were expressed
as nanomoles of glycerol per 106 cells and μEq/L of
free FA per well for glycerol and FFA, respectively.
Incorporation of [1-14C]-palmitate into triacylglycerol
KRH (Krebs Ringer Hepes bicarbonate) buffer, pH 7.4,
containing 1% BSA and 2 mM glucose plus palmitate
(200 μM), saturated with a gas mixture of 95% O2 and
5% CO2, was added to 3 T3-L1 cells after 9-day treat-
ment with FA or vehicle. [1-14C]-Palmitate was then
added to the buffer (1850 Bq/tube or well) and left for
2 h at 37 °C. Cells were then washed three times with
phosphate buffered saline (PBS) and Dole’s reagent
containing isopropanol:n-heptane:H2SO4 (4:1:0.25 vol/
vol/vol) was added to the remaining reaction mixture for
lipid extraction.
The mixture was transferred to polypropylene tubes,
which were vortexed three times during the following
30 min. After adding n-heptane (1.5 mL) and distilled
water (1.5 mL), tubes were vortexed and the mixture
was decanted for additional 5 min. The upper phase was
collected (in duplicates) and transferred to a scintillation
vial for determination of radioactivity trapped into TAG
using a β-counter (1450 LSC, Counter MicroBeta, Trilux;
PerkinElmer). Results were expressed as nanomoles of FA
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per 106 cells. Similar procedure has been used in our pre-
vious studies [18].
Decarboxylation of [1-14C]-palmitate (fatty acid oxidation)
Differentiated 3 T3-L1 cells (after 9-day treatment with
FA or vehicle) were incubated in KRH buffer (pH 7.4)
containing BSA (1%) and [1-14C]-palmitate (50 μM,
1850 Bq/tube or well), saturated with a gas mixture of
95% O2 and 5% CO2, for 2 h, at 37 °C. Prior to 2 h incu-
bation period, each well was covered with a piece of
Whatman filter paper and the plate was sealed with par-
afilm to maintain the atmosphere saturated with the gas
mixture. Following the 2 h incubation, the filter paper
was soaked with 0.1 mL of ethanolamine to trap the
CO2 produced, and 0.2 mL of 8 N H2SO4 was injected
into the wells with the aid of a needle to rupture the
cells. After 45 min of CO2 trapping, the filter paper was
removed and transferred to scintillation vials for radio-
activity counting [23, 24]. Results were expressed as
nanomoles of oxidized [1-14C]-palmitate per 106 cells.
Oxygen consumption
Oxygen consumption rates in intact cells were measured
as an indication of mitochondrial respiratory activity.
After 9-day treatment with palmitic acid (100 μM), pal-
mitoleic acid (100 μM) or vehicle, 3 T3-L1 cells were
gently tripsinised, re-suspended in KRH (pH 7.4) con-
taining BSA (0.1%), and transferred to the oxygraph
(OROBOROS Oxygraph-2 k). The oxygraph chambers
were previously equilibrated with KRH containing BSA
0.1% at 37 °C. Carbonyl cyanide m-chlorophenyl hydra-
zine (CCCP, 1 μM f.c.) was added as positive control for
maximal respiratory rate (uncoupling) determination.
Oxygen consumption rates were normalized by cell
number and expressed as % of the control [25]. Oxygen
consumption was also measured in mature 3 T3-L1
adipocytes (9 days after differentiation) treated for 24 h
with palmitoleic acid (200 μM) or vehicle.
ATP content determination
ATP content was determined in 3 T3-L1 cell lysates after
9 days of treatment with FA or vehicle (in the presence or
absence of etomoxir) using an ATP bioluminescence assay
kit (Roche, Mannheim, Germany). Measurements were per-
formed in a luminometer (Biotech, model: Synergy HT).
Results were normalized by cell number and expressed as
percentage of control [26].
Western blot analysis
After treatment with FA or vehicle for 9 days, 3 T3-L1 cells
were homogenized and processed in buffer composed in
mM by: 50 HEPES, 40 NaCl, 50 NaF, 2 EDTA, 10 sodium
pyrophosphate, 10 sodium glycerophosphate, 2 sodium
orthovanadate, and 1% Triton-X100 and EDTA-free
protease inhibitors. Identical amounts of protein aliquots
from 3 T3-L1 cell lysates were resolved on Nupage gradi-
ent gels (4–12%, Invitrogen Life Technologies) and trans-
ferred to nitrocellulose membranes. After blockage with
5% milk for 1 h, membranes were overnight incubated at
4 °C with the following primary antibodies: mitochondrial
complex I subunit NDUFB8 (20 kDa), complex II subunit
30 kDA (30 kDa), complex III subunit Core 2 (48 kDa),
COXIV subunit I (40 kDa), complex V ATP synthase
subunit alpha (53 kDa) (OXPHOS kit, MitoSciences, Inc.)
and gamma-tubulin (~ 50 kDa #5886, Cell Signaling,
Beverly, MA, USA) in 5% milk (1:1000). After wash-
ing, membranes were subsequently incubated with
appropriate peroxidase-conjugated secondary antibody
(1:5000) for 1 h and developed using the ECL en-
hanced chemiluminescence substrate (GE Healthcare Life
Sciences, Björkgatan, Uppsala). Densitometric analyses
were performed using the ImageJ software (National
Institutes of Health, Bethesda, MD).
RNA extraction, reverse transcription and quantitative
real-time PCR (real-time qRT-PCR)
Total RNA from 3 T3-L1 cell lysates was extracted using
Trizol (Invitrogen Life Technologies), analyzed for quality
on agarose gel and absorbance ratios of 260/280 nm and
260/230 nm, and reverse transcribed to cDNA using the
SuperScript III cDNA kit (Invitrogen Life Technologies).
Gene expression was evaluated by real-time qRT-PCR
using a Rotor Gene (Qiagen, Roermond, Netherlands) and
SYBR Green as fluorescent dye (Qiagen) with 36B4/Rplp0
as housekeeping gene. The reaction conditions were as
follows: 95 °C for 5 min, then 40 cycles of 95 °C for 5 s
and 60 °C for 10 s. PCR products were run on agarose gel
to confirm the size of the fragment and specificity of
amplification. Primers used were: Pnpla2 (5′-3′ sense:
GGTCCTCTGCATCCCTCCTT; 5′-3’antisense: CTGTC
CTGAGGGAGATGTC), aP2 (5′-3′ sense: AAGGTGAA
G AGCATCATAACCCT; 5′-3’antisense: TCACGCCTTT
CATAACACATTCC) and 36B4 (5′-3′ sense: TAAAGA
CTGGAGACAAGGTG; 5′-3’antisense: GTGTACTCAG
TCTCCAC AGA). Data were obtained as ct values (ct =
cycle number at which logarithmic PCR plots cross a
calculated threshold line) and used to determine Δct
values (Δct = (ct of the target gene) - (ct of the housekeep-
ing gene). Data were expressed as arbitrary units using the
following calculation: [expression = 1000×(2-Δct) arbitrary
units (AU)].
Mitochondrial mass determination
The methodology was based on the protocol used by
Shen et al. [25]. A fluorescent probe (Mito-Tracker
Green FM; Molecular Probes, Eugene, OR, USA) was
used to determine the mitochondrial mass of adipocytes
[27]. Mature adipocytes (9 days of differentiation) were
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treated with palmitic or palmitoleic acid, trypsinised and
centrifuged at 1500×g, 4 °C, for 5 min, resuspended in
KRH buffer containing 0.1% BSA (w/v) and then incu-
bated with 0.1 μmol/L MitoTracker Green FM in KRH
buffer for 30 min at 37 °C. Cells were centrifuged at
1500×g, 4 °C, for 5 min and resuspended in 400 μL of
fresh KRH buffer. Fluorescence measurements were
carried out in CALIBUR cytometer (BD) in the FL1
channel. Ten thousand events were analyzed per experi-
ment. Data were analyzed using Cell Quest software.
Citrate synthase activity assay
Citrate synthase (EC 4.1.3.7) maximum activity was de-
termined as previously described by Alp et al. [28].
Briefly, after 9 days treatment with FA or vehicle, 3 T3-
L1 cells were homogenized (vortex) in extraction buffer
containing Tris-HCl (50 mM), EDTA (1 mM), leupep-
tin (50 μM), and aprotinin (5 μM), pH 7.4, and centri-
fuged (16,000 g, 30 s, 4 °C). The assay buffer consisted
of Tris HCl (100 mM), DTNB (0.2 mM), acetyl-CoA
(100 mM), and Triton (1%), pH 6.5. The reaction was
started by adding 10 uL of oxaloacetic acid (500 mM)
25 °C. The absorbance was monitored for 10 min at
420 nm. Protein concentration in the supernatants was
determined using a BCA® protein assay kit (PIERCE
Biotechnology, Rockford, IL). The maximal enzyme
activity was expressed as micromoles per minute per
microgram of protein.
Statistical analysis
Results are expressed as mean ± SEM. One-Way ANOVA
followed by Tukey post-hoc test were used to compare
the effects of different treatments. Analysis was performed
using GraphPad Prism 5.0 software (GraphPad Software,
Inc., San Diego, CA, USA). The level of significance was
set at p ≤ 0.05.
Results
First, we examined the effect of 9-day treatment with
palmitoleic or palmitic acid on 3 T3-L1 adipocyte lipoly-
sis. Palmitoleic acid increased both basal (by 3-fold) and
stimulated (by 3.5-fold) lipolysis as measured by the
glycerol released to the medium [mean ± SEM, Basal (ve-
hicle: 828.9 ± 95.4; 16:1n7: 3027.2 ± 511) and stimulated
(vehicle: 1760.3 ± 174; 16:1n7: 6077.7 ± 822) nMol/106
cells, p < 0.05] (Fig. 1a and b, respectively). Pnpla2
mRNA levels were significantly increased (by 30%) in
cells treated with palmitoleic acid (Fig. 1c). We further
investigated whether 16:1n7 would also promote an in-
crease in free fatty acid (FFA) release by these cells (dic-
tated by a glycerol/FA proportion of 1:3, as products of
TAG hydrolysis). Palmitoleic acid did not cause signifi-
cant increase of FFA release into the medium, that is, no
difference was observed among the groups. Interestingly,
this profile was slightly altered by pretreatment with eto-
moxir (a potent inhibitor of fatty acid mitochondrial up-
take and oxidation), since 16:1n7 + etomoxir treated cells
presented an increase by 5% in the FFA release into the
medium (mean ± SEM, 16:1n7: 59.2 ± 0.8; 16:1n7 + eto-
moxir: 63.3 ± 0.44 μMol/L, p < 0.05) (Fig. 3b). We did not
observe any effect of palmitic acid on lipolytic activity.
We hypothesized that palmitoleic acid should boost
TAG lipolysis/FA re-esterification cycle. To test this
hypothesis, we analyzed if FA esterification was raised
in cells treated with palmitoleic acid. Indeed, an in-
crease of [1-14C]-palmitate incorporation into TAG
(by 40%) was observed in cells treated with palmito-
leic acid (mean ± SEM, vehicle: 23.42 ± 0.5; 16:1n7:
28.73 ± 0.8 nMol/106 cells, p < 0.05) (Fig. 2a). More-
over, aP2 mRNA levels were positively regulated by
palmitoleic acid (Fig. 2b). These results show that FA
incorporation into TAG is increased in 3 T3-L1
adipocytes treated with palmitoleic acid. No effect on
the synthesis of TAG was observed in cells treated
with palmitic acid.
a b c
Fig. 1 Basal (a) and isoproterenol-stimulated (b) lipolysis measuring by release of glycerol (nanomoles per 106 cells). c mRNA levels of Pnpla2
gene (arbitrary units). Experiments performed in differentiated 3 T3-L1 adipocytes treated for 9 days with vehicle, palmitic acid (16:0, 100 μM) or
palmitoleic acid (16:1n7, 100 μM). Results are means ± SEM. * P < 0.05 16:1n7 vs. all groups. The results are the average of 3
independent experiments (n = 4/experiment)
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Next, we investigated if palmitoleic acid could en-
hance FA beta-oxidation. The conversion of [14C]-
palmitate to CO2 was raised by 30% in cells treated
with palmitoleic acid when compared to control cells
(mean ± SEM, vehicle: 0.8 ± 0.033; 16:1n7: 1.03 ± 0.05
nMol/106 cells, p < 0.05) (Fig. 3a). No change in FAO
was observed in cells treated with palmitic acid when
compared to control. Disruption of fatty acid oxida-
tion by etomoxir in a dose of 40 μM was confirmed
in this experiment by partial attenuation (~ 25%) of
fatty acid oxidation.
Other mitochondrial parameters, such as ATP levels
and oxygen consumption, were also measured in 3 T3-L1
cells. FA oxidation is a metabolic pathway that requires
oxygen to take place. We performed oxygen consump-
tion measurements in 3 T3-L1 adipocytes treated with
fatty acids using a modular system for high-resolution
respirometry (HRR), the Oroboros Oxygrapk-2 k (O2k).
Oxygen consumption was raised in cells treated with
palmitoleic acid for 9 days (by 13%, Fig. 4a) and 24 h
(by 10%, Fig. 4b). So, palmitoleic acid stimulates basal
energetic metabolism in white adipocytes. Palmitic acid
treatment did not affect oxygen consumption in any of
the conditions studied.
We further investigated the palmitoleic effects on ATP
content. 16:1n7, but not 16:0 treatment of the cells, raised
ATP levels by 17% (mean ± SEM, vehicle: 100 ± 1.72;
16:1n7: 119.8 ± 1.51 percentage of control, p < 0.05) (Fig. 5).
We hypothesized that raised FAO, secondary to raised
lipolysis promoted by 16:1n7, elevates ATP production
(corroborating oxygen consumption) in a magnitude cap-
able of overcome its consumption (raised by the exacerba-
tion of TAG/FA cycle). This hypothesis is supported here,
by the experiments performed under pretreatment of the
cells with etomoxir, that completely prevented the incre-
ment on ATP content induced by palmitoleic acid (Fig. 5).
a b
Fig. 2 a [1-14C]-palmitate incorporation into TAG (nanomoles of incorporated [1-14C]-palmitate per 106 cells) and b mRNA levels of aP2 (arbitrary
units). Experiments performed in differentiated 3 T3-L1 adipocytes treated for 9 days with vehicle, palmitic acid (16:0, 100 μM) or palmitoleic acid
(16:1n7, 100 μM). Results are means ± SEM. * P < 0.05 16:1n7 vs. all groups. The results are the average of 3 independent
experiments (n = 6/experiment)
a b
Fig. 3 a Conversion of [1-14C]-palmitate into CO2 (nanomoles of converted [1-
14C]-palmitate into CO2 per 10
6 cells) and b Free fatty acids
released under lipolysis (μMol per liter per well). Experiments performed in 3 T3-L1 adipocytes under 9-days treatment with vehicle, etomoxir
(40 μM), palmitic acid (16:0, 100 μM) or palmitoleic acid (16:1n7, 100 μM). Results are means ± SEM. * P < 0.05 vs. all groups. The results are the
average of 3 independent experiments (n = 4/experiment)
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Since the augmented ATP concentration observed in
our studies suggest an increment in mitochondrial
OXPHOS efficiency, we next evaluated protein expres-
sion of subunits representing complex II, III, and V of
the mitochondrial electron transport chain. Complex II
and III were positively modulated by palmitoleic acid (by
54% and by 36%, respectively), but not by palmitic acid,
when compared with the control group (Fig. 6b and c).
Likewise, complex V was positively modulated by palmi-
toleic acid (by 40%) when compared to the control
group (Fig. 7e). However, palmitoleic acid did not elicit
any change in the content of mitochondrial complexes I
and IV (Fig. 6a and d, respectively).
Mitochondria mass was evaluated by flow cytometry,
according to the methodology proposed by Shen and col-
leagues [25]. A decrease of ~ 10% in mitochondria mass
was observed in cells treated with palmitoleic acid. There
was no effect of palmitic acid on this parameter (Fig. 7a).
Another parameter to measure mitochondria content is
citrate synthase activity. Palmitoleic acid (but not palmitic
acid) led also to a reduction of ~ 10% in citrate synthase
activity (mean ± SEM, vehicle: 0.031 ± 0.0005; 16:1n7:
0.024 ± 0.0008 μMol/min/μg of protein, p < 0.05) (Fig. 7b),
when compared with the control group.
Discussion
3 T3-L1 adipocytes were treated with palmitic acid or pal-
mitoleic acid, being the latter recently described to induce
important effects on carbohydrate and lipid metabolism in
liver and skeletal muscle [12, 15, 29, 30]. We have previ-
ously demonstrated that palmitoleic acid controls import-
ant metabolic processes also in adipose tissue. We
reported increased lipolysis and glucose uptake, together
with changes in expression of related genes and proteins
(ATGL, HSL, AMPK and GLUT4) in white adipocytes
[18, 19]. In the present work, we observed that palmitoleic
acid modulates other aspects of adipocyte metabolism,
mainly mitochondria bioenergetics. Palmitoleic acid (but
not palmitic acid) enhanced energy expenditure in adipo-
cytes through TAG/FA cycle stimulation, FA oxidation,
oxygen consumption and increased protein expression of
subunits representing complex II, III, and V of the mito-
chondrial electron transport chain. The treatment of the
adipocytes with palmitic acid (16:0), different from palmi-
toleic (16:1n7), showed no marked effect on the parame-
ters herein studied.
An increase in both basal and isoproterenol-stimulated
lipolysis, together with augmented gene expression of
the Pnpla2, were observed in 3 T3-L1 cells treated with
palmitoleic acid (9 days, from the induction of preadipo-
cyte differentiation) when compared to the palmitic acid
a b
Fig. 4 Oxygen consumption by 3 T3-L1 adipocytes under (a) chronic (9 days) and b acute (24 h) treatments with vehicle, palmitic acid (16:0,
100 μM, respectively) or palmitoleic acid (16:1n7, 200 or 100 μM, respectively). Results expressed as percentage of control. Results are presented
as means ± SEM. * P < 0.05 16:1n7 vs. all groups. The results are the average of 3 independent experiments (n = 6/experiment)
Fig. 5 ATP content on 3 T3-L1 adipocytes under 9-day treatment
with vehicle, etomoxir (40 μM), palmitic acid (16:0, 100 μM) or
palmitoleic acid (16:1n7, 100 μM). Results expressed as percentage of
control. Results are means ± SEM. * P < 0.05 16:1n7 vs. all groups.
The results are the average of 3 independent
experiments (n = 4/experiment)
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and control groups. These findings corroborate previous
ex vivo results obtained by our group [18]. We have
shown that there is an increase of lipolysis in primary
adipocytes extracted from epididymal fat pads of mice
treated with palmitoleic acid (by gavage) for 10 days and
also, in mature (6 days post-differentiation) 3 T3-L1 cells
treated with palmitoleic acid (by 24 h), via a PPARα-
dependent mechanism. The increment in lipolysis pro-
moted by palmitoleic acid was estimated according to
the concentration of glycerol released into the medium.
A concomitant increment of FFA released from adipo-
cytes [dictated by a glycerol/FA proportion of 1:3, as
products of TAG hydrolysis] treated with palmitoleic
acid was not observed. This suggests that the fatty acids
originated from lipolysis of cells treated with palmitoleic
acid could be used in other metabolic pathways such as:
(1) re-esterification, (2) mitochondrial oxidation or (3)
mitochondrial uncoupling, including the possibility of
overlapping pathways. We ruled out mitochondrial un-
coupling due to the fact that cellular ATP levels were
augmented upon palmitoleic acid treatment (Fig. 5) and
UCP1/2 mRNA levels are not altered under this condi-
tion (data not shown).
To test the hypothesis 1, we analyzed if FA esterifica-
tion was increased in cells treated with palmitoleic acid
for 9 days. Palmitoleic acid did increase [1-14C]-palmi-
tate incorporation into TAG as well as aP2 mRNA levels
in adipocytes. aP2 gene encodes a protein involved in
a
d
b c
e
Fig. 6 Total content of subunits representing OXPHOS proteins complexes analyzed by western blot. a Complex I. b Complex II. c Complex III. d
CoxIV. e Complex V. Experiments were performed in differentiated 3 T3-L1 adipocytes treated for 9 days with vehicle, palmitic acid (16:0, 100 μM)
or palmitoleic acid (16:1n7, 100 μM). Results expressed as arbitrary units. Results are presented as means ± SEM. * P < 0.05 16:1n7 vs. all groups,
# P < 0.05 16:1n7 vs. vehicle. The results are the average of 3 independent experiments (n = 4/experiment)
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FA uptake and transport to be then associated to coen-
zyme A (a reaction catalyzed by acyl-CoA synthetase)
to generate acyl-CoA. Corroborating these findings, we
demonstrated an increase in the generation of glycerol
3-phosphate (G3-P) via glycolysis (required for esterifi-
cation of fatty acids to TAG), as evidenced by the
higher rates of glucose incorporation into the glycerol
fraction of TAG [18]. In another recent work published
by our group [19] an increase of glucose uptake by
adipocytes, via a mechanism that involves AMPK, pro-
moted by palmitoleic acid was demonstrated. This ob-
servation is compatible with increased G3-P formation
from glucose, since there was not seen any increase in
gene expression of the glyconeogenic regulatory enzyme
PEPCK or in glycerol kinase activity in this study, the two
other possible sources of G3-P [31]. These results suggest
that palmitoleic acid promotes FA re-esterification and
TAG/FA futile cycle stimulation.
A concomitant increase in lipolysis and FA re-
esterification implies in stimulation of the substrate cycle
(or “futile” cycle) TAG/FA cycle [32, 33]. In mammals, an
increase in this cycle activity together with raised fatty acid
oxidation can lead to augmented basal metabolic rate
(BMR) and total energy expenditure [34] as well as greater
sensitivity to hormonal control of energy metabolism (e.g.
lipolytic and lipogenic activities). Additionally, the stimula-
tion of this cycle is a mechanism associated with induction
of thermogenesis during cold exposure [35] and also when
plasma leptin levels are high [32].
In the next step, we investigated if palmitoleic acid
could enhance FA beta-oxidation and oxygen con-
sumption. Maassen, Romijn and Heine [36] suggested
that FA oxidation in adipocytes might also contribute
to the retention of FA in these cells, thus avoiding
excessive release of FA into the circulation when lip-
olysis is stimulated reducing lipotoxicity. We observed
an increase (by 30%) in FA oxidation in 3 T3-L1
adipocytes treated with palmitoleic acid. This effect
maybe underestimated due to the fact that palmitoleic
acid can compete with labeled [1-14C]-palmitate
(50uM) added to the medium during this test for the
beta-oxidation pathway.
Despite the fact that some studies describe FA oxidation
as a minor metabolic pathway in white adipocytes, espe-
cially when compared to FA re-esterification [37–39], Dib,
Bugge and Collins [40] claim that FA oxidation in WAT is
not negligible and contributes from 5 to 10% of the BMR
in lean and obese adults, respectively. Noteworthy, the
percentage of endogenous FA oxidized in primary rat
white adipocyte was calculated and found to be around
0.2%, what seems small when compared to re-esterified
(~ 50%) and released endogenous FFA (~ 50,1%) [41]. We
estimated herein the amount of FFA released by the cells,
which were around 40 nmoles/106 cells. The esti-
mated FFA released is much lower than the amount
of glycerol released (by 70-fold) but it is much higher
than the amount of CO2 generated (~ 1 nmol/10
6
cells). This finding corroborates the data that FFA re-
esterification and endogenously released FFA are the
major pathways when compared to FFA oxidation.
Anyway, pretreatment with etomoxir, that has been
shown to bind CPT-1 with high affinity, thereby pre-
venting mitochondrial uptake of fatty acids [42],
caused an increment in the FFA release into the
medium by the cells treated with palmitoleic acid.
The disruption of fatty acid oxidation by etomoxir
was confirmed here, by the attenuation of fatty acid
oxidation.
Wang and cols [41] claim that FFA oxidation assays
are usually performed during a short period of time (a 2-h
period or so) and, if extrapolated to years, this oxidative
pathway could reduce more than 1 kg of fat mass per
50 kg of fat mass per year in humans depending on if
there is combined fasting or not. Therefore, WAT FAO
a b
Fig. 7 a Mitochondrial mass (percentage of florescence). b Citrate synthase activity (micromoles per minute per microgram of protein).
Experiments performed in differentiated 3 T3-L1 adipocytes treated for 9 days with vehicle, palmitic acid (16:0, 100 μM) or palmitoleic acid
(16:1n7, 100 μM). Results are means ± SEM. * P < 0.05 16:1n7 vs. all groups. The results are the average of 3–4 independent
experiments (n = 6/experiment)
Cruz et al. Lipids in Health and Disease  (2018) 17:55 Page 8 of 12
might be not so negligible as previously thought to be. Ac-
tually, efficient mitochondrial WAT FAO may increase re-
spiratory capacity, reduce adipocyte size, enhance lipolysis
and reduce lipotoxicity [6, 38, 43]. A recent study with
human twins showed that adiposity is correlated with
downshifting of FAO and that, indeed, mitochondrial bio-
genesis, oxidative metabolic pathways and OXPHOS pro-
teins in subcutaneous adipose tissue are downregulated in
acquired obesity [44]. Altogether these studies corroborate
the hypothesis that mitochondrial WAT FAO stimulation
has relevant effects on body energy balance.
Together with increased FAO, an increment in basal
O2 consumption was observed in 3 T3-L1 cells treated
with palmitoleic acid, which suggests an increase in
BMR of these cells. This enhancement in oxygen con-
sumption could be explained by an increase in FAO,
mitochondrial uncoupling or both [45].
The augmentation in O2 consumption observed in
the present study supports the consistent raise in FAO
catabolic pathway. In addition, cellular ATP levels were
raised by 17% as well as protein levels of the subunit
ATP-5A of the OXPHOS complex V (ATP synthase,
Fig. 6e) upon palmitoleic acid treatment. Pretreatment
with etomoxir completely prevented this effect, dem-
onstrating the dependent effect of FAO increase for
the palmitoleic effects here observed. Altogether, the
raise in all these mitochondrial parameters: oxygen
consumption, FAO and ATP generation, points out to
enhanced mitochondrial oxidative phosphorylation
efficiency [46] upon palmitoleic acid treatment. Al-
though the palmitoleic acid effects seems mild,
according Gao and colleagues [47] mitochondria do
not require major changes to reflect a prominent
metabolic effect. In contrast, abrupt mitochondrial
changes are toxic and induce cell death. This work
showed that both sudden increases or decreases cause
mitochondrial damage by high levels of glucose and
free fatty acids in 3 T3-L1 adipocytes.
At first, palmitoleic acid-induced increase in cellular
ATP levels seems odd since raised AMP/ATP ratio is
the main factor that leads to AMPK phosphorylation
and activation. In addition, given the crucial role of
the acyl-CoA synthetase in the re-esterification of FA
released from lipolysis [48], this finding looks indeed
unexpected. Acyl-CoA synthetase catalyzes the activa-
tion of 1 FA in 1 acyl-CoA, consuming 1 ATP (1 AMP
and pyrophosphate). In fact, it utilizes two equivalents
of ATP since pyrophosphate is cleaved into 2 inor-
ganic phosphate molecules, breaking a high-energy
phosphate bond. Nevertheless, FAO generates NADH
and FADH2, which enter the electron transport chain to
produce ATP. Our hypothesis is that raised FAO (second-
ary to raised lipolysis) promoted by 16:1n7, elevates ATP
production (corroborating oxygen consumption increase)
in a magnitude capable of overcome its consumption
(raised by the exacerbation of TAG/FA cycle). This hy-
pothesis is supported here, by the experiments performed
under pretreatment of the cells with etomoxir, that com-
pletely prevented the increment on ATP content induced
by palmitoleic acid. Actually, Baldwin et al. [49] calculated
that the energy required for TAG/FA cycle is around 8
molecules of ATP per release and re-esterification of 3
molecules of FA (2,7 ATP/FA). This energetic demand
could be provided by mitochondria FAO (fasting) and glu-
cose oxidation (fed state) [50]. Indeed, the effectiveness of
fuel oxidation by mitochondrial relies on mitochondria
content, mitochondrial activity and mitochondrial effi-
ciency to synthesize ATP from the oxidation of substrates
[46]. Noteworthy, relative to their dry mass, FA provide
twice as much ATP as carbohydrates: six times more
when comparing stored FA to stored glycogen [51]. It is
importante to emphasize that cell lines in culture, includ-
ing 3 T3-L1 cells, display a high rate of glycolysis. How-
ever, we can assume herein that glycolysis is not
responsible for the increament in ATP levels, since the
results showed that when CPT1 was inhibited in cells
treated with palmitoleic acid, the ATP levels increase was
completely abolished.
The augmented ATP concentration observed corrob-
orates our data of an increment in mitochondrial
OXPHOS efficiency (increased protein expression of
subunits representing OXPHOS complex II, III and IV)
in cells treated with 16:1n7. Raised ATP consumption is
observed when lipolysis occurs simultaneously with FA
re-esterification (TAG/FA cycle) [52]. As a paradox,
augmented basal and isoproterenol stimulated lipolysis
(promoted by 16:1n7) increases AMP/ATP ratio, which
is known to promote AMPK activation [53], that, in
turn, would stimulate catabolic pathways in order to in-
crease ATP production, corroborating the data of raised
beta-oxidation and oxygen consumption demonstrated
herein. These findings also support the previous data
shown by our group that 16:1n7 led to an increase on
glucose uptake and oxidation associated with AMPK
activation [19].
WAT mitochondria are potential targets in the search
for the development of therapies to prevent and treat
obesity, inflammation, insulin resistance and related
disorders [6, 40, 54]. Ahmadian et al. (56) suggested that
augmented lipolysis could result in a change in adipocyte
metabolism via greater use of FA and enhanced energy
expenditure, protecting against obesity [55]. The fact that
palmitoleic acid reduced citrate synthase activity corrobo-
rates the results of decreased mitochondrial mass under
the effect of this fatty acid, suggesting more efficient mito-
chondria, although fewer in number, in these adipocytes
treated with palmitoleic acid. Indeed, relevant metabolic
parameters of these cells were increased, such as oxygen
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consumption, beta-oxidation, lipolysis and lipogenesis,
which corroborates an increased intrinsic mitochondrial
function as a physiologic adaptation. It is currently ac-
cepted that mitochondria are dynamic organelles, which
adjust according to the cell’s energy demand.
Mitochondrial function (particularly OXPHOS un-
coupling and FA oxidation) is considered a crucial
factor to improve systemic insulin sensitivity [56–59].
Mitochondrial oxidative capacity in WAT correlates
negatively with adiposity [50]. For example, a WAT
knockout mouse for Liver Receptor X alpha (ATaKO
mouse) was generated and presented more weight gain
and fat mass on a high-fat diet compared with wild-
type controls as a result of the decrease in WAT lipo-
lytic and oxidative capacities [60]. Accordingly, LXR
activation in vivo and in vitro led to decreased WAT
adipocyte size and increased glycerol release from
primary adipocytes, respectively, with a concomitant in-
crease in oxygen consumption [40]. Thereby, novel
compounds with potential to stimulate lipolysis, TAG/
FA cycle, FA oxidation in WAT are desired in therapies
focusing obesity and related diseases.
Conclusions
In conclusion, our data show that palmitoleic acid
plays an important role on WAT metabolic and mito-
chondrial function, suggesting an increase in energy
expenditure of adipocytes by TAG/FA cycle acceler-
ation, FA oxidation and oxygen consumption and,
thus, raised cell energy metabolism. We presented
herein evidence indicating that palmitoleic acid, by
concerted action on lipolysis, mitochondrial FA oxida-
tion, ATP content and oxygen consumption, contrib-
utes to enhance white adipocyte energy expenditure
and could be considered as a possible candidate for
clinical research related to adipose tissue (Fig. 8). We
believe that palmitoleic acid treatment alone or its
combination with caloric restriction and/or exercise is
a promise for future obesity treatment/prevention.
Nevertheless, the mechanisms involved in palmitoleic-
induced TAG/FA cycle stimulation via mitochondria
function have to be fully elucidated.
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